Methodology: each issue's direction is a live signal — long/short opens or holds a position, neutral means flat, and every direction change opens, flips, or closes it. Returns are direction-aware (a short gains when the price falls) and compound across positions from first observation to the latest issue. "Price move" is the stock's own raw change, shown separately. Neither represents actual portfolio performance.
Brief History (3 issues)
Up 43.09% to a $6.39 52-week high on 5.65x volume after a 46.1% month with RSI at 69.8; cell therapy commercialization isn't yet profitable and the move has no valuation anchor. Sidelines.
A biotech momentum name up 38% on the month at RSI 71 as TIL-therapy commercialization ramps — better to wait for $5 than chase
Up 7.3% to $5.00, the cell-therapy spec crowd extending a +28.9% monthly bounce. The action around the $5 mark is entertainment, not a setup. No bet.